WO2022244580A1 - 免疫賦活剤及びグルカン組成物の製造方法 - Google Patents
免疫賦活剤及びグルカン組成物の製造方法 Download PDFInfo
- Publication number
- WO2022244580A1 WO2022244580A1 PCT/JP2022/018278 JP2022018278W WO2022244580A1 WO 2022244580 A1 WO2022244580 A1 WO 2022244580A1 JP 2022018278 W JP2022018278 W JP 2022018278W WO 2022244580 A1 WO2022244580 A1 WO 2022244580A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucan
- mass
- less
- content
- immunostimulant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 66
- 229920001503 Glucan Polymers 0.000 title claims description 60
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 98
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 63
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 63
- 210000005253 yeast cell Anatomy 0.000 claims abstract description 37
- 229920000057 Mannan Polymers 0.000 claims abstract description 26
- 229960001438 immunostimulant agent Drugs 0.000 claims description 67
- 239000003022 immunostimulating agent Substances 0.000 claims description 67
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 42
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 41
- 229920000310 Alpha glucan Polymers 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 24
- 229920002527 Glycogen Polymers 0.000 claims description 20
- 229940096919 glycogen Drugs 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000021995 interleukin-8 production Effects 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 230000002434 immunopotentiative effect Effects 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000047 product Substances 0.000 description 27
- 230000001737 promoting effect Effects 0.000 description 16
- 230000016396 cytokine production Effects 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- -1 that is Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001609213 Carassius carassius Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241001154287 Hucho taimen Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Definitions
- the present invention relates to a method for producing an immunostimulant and a glucan composition.
- JP-A-2010-533479 proposes a method for preparing a glucan preparation by combining enzymatic treatment and acid/alkali hydrolysis treatment, which has a high glucan content and is said to be suitable for industrial use.
- An object of one aspect of the present invention is to provide an immunostimulatory agent that contains ⁇ -glucan derived from the yeast cell wall and has a high immunostimulatory effect.
- the first aspect is an immunostimulant containing ⁇ -glucan derived from the yeast cell wall and having a ⁇ -glucan content of 25% by mass or more and 45% by mass or less.
- the immunostimulant further contains mannan, the content of mannan in the immunostimulator may be 5% by mass or more and 20% by mass or less, and the content ratio of the mannan to ⁇ -glucan is 0.1 or more. may be less than one.
- the immunostimulant further comprises ⁇ -glucan, the content of ⁇ -glucan in the immunostimulator may be 7% by mass or more and 12% by mass or less, and the content ratio of ⁇ -glucan to ⁇ -glucan may be 0.15 or more and 0.55 or less.
- the ⁇ -glucan contains glycogen
- the content of glycogen in the immunostimulant may be 4% by mass or more and 10% by mass or less
- the content ratio of glycogen to ⁇ -glucan is 0.16 or more and 0.16 or more. It may be 5 or less.
- a second aspect is an interleukin-8 production promoter containing ⁇ -glucan derived from the yeast cell wall and having a ⁇ -glucan content of 25% by mass or more and 45% by mass or less.
- mannan is further included, the content of mannan in the interleukin-8 production promoter may be 5% by mass or more and 20% by mass or less, and the content ratio of mannan to ⁇ -glucan is 0.1 or more and 1 may be less than
- ⁇ -glucan may be further included, the content of ⁇ -glucan in the interleukin-8 production promoter may be 7% by mass or more and 12% by mass or less, and the content ratio of ⁇ -glucan to ⁇ -glucan may be It may be 0.15 or more and 0.55 or less.
- the ⁇ -glucan contains glycogen
- the content of glycogen in the interleukin-8 production promoter may be 4% by mass or more and 10% by mass or less
- the content ratio of glycogen to ⁇ -glucan is 0.16. It may be greater than or equal to 0.5 or less.
- a third aspect includes washing the yeast cell wall under alkaline conditions to obtain a first processed product, heat-treating the first processed product under alkaline conditions to obtain a second processed product, and and recovering a third processed product as a solid content, wherein the third processed product has a ⁇ -glucan content of 25% by mass or more and 45% by mass or less.
- the heat treatment under alkaline conditions may be performed under conditions of pH 8 or higher and pH 14 or lower and 70° C. or higher and 110° C. or lower.
- yeast cell walls may include cell walls derived from brewer's yeast or baker's yeast.
- washing under alkaline conditions may include adjusting the pH of the yeast cell wall-containing washing solution to pH 8 or higher and pH 14 or lower, and performing solid-liquid separation with a centrifugal separator while adding water.
- the third processed material may be recovered by subjecting the second processed material to solid-liquid separation by centrifugation.
- the glucan composition to be produced may be an immunostimulator or an interleukin-8 production promoter.
- an immunostimulatory agent that contains ⁇ -glucan derived from the yeast cell wall and has a high immunostimulatory effect.
- FIG. 1 is a diagram showing interleukin-8 production promoting effects of glucan compositions according to Example 1 and Comparative Example 1.
- FIG. 1 is a diagram showing interleukin-8 production promoting effects of glucan compositions according to Example 1, Comparative Examples 2 and 3.
- FIG. 1 is a diagram showing interleukin-8 production promoting effects of glucan compositions according to Example 1, Comparative Examples 2 and 3.
- the term "process” is not only an independent process, but even if it cannot be clearly distinguished from other processes, it is included in this term as long as the intended purpose of the process is achieved.
- the content of each component in the composition means the total amount of the plurality of substances present in the composition unless otherwise specified when there are multiple substances corresponding to each component in the composition.
- the upper and lower limits of the numerical ranges described herein can be combined by arbitrarily selecting the numerical values exemplified as the numerical ranges.
- embodiments of the present invention will be described in detail. However, the embodiments shown below exemplify methods for producing an immunostimulant and a glucan composition for embodying the technical idea of the present invention. It is not limited to the method of producing the glucan composition.
- the immunostimulant is a glucan composition containing ⁇ -glucan derived from the yeast cell wall and having a ⁇ -glucan content of, for example, 25% by mass or more and 45% by mass or less.
- the immunostimulant according to the present embodiment has an excellent immunostimulatory effect by containing a predetermined content of ⁇ -glucan derived from the yeast cell wall. As a result, not only is it expected to suppress the onset and progression of infectious diseases in livestock, humans, farmed fish, etc., but it may also provide means for reducing the threat of the emergence of drug-resistant bacteria.
- the immunostimulatory effect of an immunostimulant can be evaluated, for example, by the effect of promoting the production of cytokines involved in immunity such as interleukin. That is, the immunostimulant may be an interleukin production promoter, preferably an interleukin 8 production promoter.
- ⁇ -Glucan which constitutes an immunostimulant, is a polymer in which D-glucose is linked by glycosidic bonds, and has a linear main chain skeleton of ⁇ -1,3 bonds and side chains branched by ⁇ -1,6 bonds.
- the ⁇ -glucan that constitutes the immunostimulant is, for example, derived from the yeast cell wall, preferably obtained by hydrolyzing the yeast cell wall, and is produced by the method for producing a ⁇ -glucan composition described below. It may be included in the glucan composition.
- the content of ⁇ -glucan in the immunostimulant may be preferably 28% by mass or more, 30% by mass or more, 34% by mass or more, or 35% by mass or more.
- the content of ⁇ -glucan in the immunostimulant may preferably be 42% by mass or less, 40% by mass or less, 38% by mass or less, or 35% by mass or less.
- the content of ⁇ -glucan in this specification is a value converted to dry matter, and the content of mannan, ⁇ -glucan, glycogen, etc. below is also a value converted to dry matter.
- the immunostimulant may further contain mannan in addition to ⁇ -glucan.
- the content of mannan in the immunostimulator may be, for example, 5% by mass or more and 20% by mass or less.
- the content of mannan in the immunostimulant is preferably 7% by mass or more, 9% by mass or more, or 10% by mass or more, and is preferably 18% by mass or less, 16% by mass or less, 14% by mass or less, Or it may be 12% by mass or less.
- the content of mannan is within the above range, there is a tendency that a higher immunostimulatory effect is obtained.
- the content ratio of mannan to ⁇ -glucan in the immunostimulant may be, for example, 0.1 or more and less than 1 from the viewpoint of the effect of promoting interleukin production.
- the content ratio of mannan to ⁇ -glucan in the immunostimulant is preferably 0.2 or more, 0.25 or more, 0.28 or more, or 0.3 or more, and preferably 0.8 or less, It may be 0.6 or less, 0.4 or less, or 0.35 or less.
- the immunostimulant may further contain ⁇ -glucan in addition to ⁇ -glucan.
- the content of ⁇ -glucan in the immunostimulator may be, for example, 7% by mass or more and 12% by mass or less.
- the content of ⁇ -glucan in the immunostimulant is preferably 8% by mass or more, 9% by mass or more, or 9.5% by mass or more, and is preferably 18% by mass or less, 11% by mass or less, 10% by mass or less. .5% by mass or less, or 10% by mass or less.
- the content ratio of ⁇ -glucan to ⁇ -glucan in the immunostimulant may be, for example, 0.15 or more and 0.55 or less from the viewpoint of the effect of promoting interleukin production.
- the content ratio of ⁇ -glucan to ⁇ -glucan in the immunopotentiator is preferably 0.18 or more, 0.2 or more, 0.24 or more, or 0.26 or more, and preferably 0.5. 0.4 or less, 0.3 or less, or 0.28 or less.
- the immunostimulant may contain glycogen as part of ⁇ -glucan.
- the content of glycogen in the immunostimulator may be, for example, 4% by mass or more and 10% by mass or less.
- the content of glycogen in the immunostimulant is preferably 5% by mass or more, 6% by mass or more, or 6.4% by mass or more, and is preferably 9% by mass or less, 8% by mass or less, or 7% by mass. or less, or 6.8% by mass or less.
- the content of glycogen is within the above range, there is a tendency that a higher immunostimulatory effect is obtained.
- the content ratio of glycogen to ⁇ -glucan in the immunostimulant may be, for example, 0.16 or more and 0.3 or less from the viewpoint of the effect of promoting interleukin production.
- the content ratio of glycogen to ⁇ -glucan in the immunostimulant is preferably 0.17 or more, 0.18 or more, or 0.182 or more, and preferably 0.25 or less, 0.22 or less, It may be 0.2 or less, or 0.19 or less.
- the total content of ⁇ -glucan and ⁇ -glucan in the immunostimulant may be, for example, 35% by mass or more and 52% by mass or less.
- the total content of ⁇ -glucan and ⁇ -glucan in the immunopotentiator is preferably 38% by mass or more, 40% by mass or more, 42% by mass or more, or 44% by mass or more, and preferably 50% by mass. 48% by mass or less, or 46% by mass or less.
- the ratio of the content of ⁇ -glucan to the total content of ⁇ -glucan and ⁇ -glucan (hereinafter also referred to as total glucan content) in the immunostimulant is, for example, 0.65 or more from the viewpoint of the effect of promoting interleukin production. It may be 0.85 or less.
- the ratio of the ⁇ -glucan content to the total glucan content in the immunostimulant is preferably 0.68 or more, 0.7 or more, 0.72 or more, 0.74 or more, 0.76 or more, or 0.78 or more, and preferably 0.82 or less, 0.8 or less, or 0.79 or less.
- the ratio of the ⁇ -glucan content to the total glucan content in the immunostimulant may be, for example, 0.14 or more and 0.35 or less from the viewpoint of the interleukin production promoting effect.
- the ratio of the ⁇ -glucan content to the total glucan content in the immunostimulant is preferably 0.16 or more, 0.18 or more, or 0.2 or more, and preferably 0.3 or less, 0 0.28 or less, 0.26 or less, 0.24 or less, or 0.22 or less.
- the ratio of the mannan content to the total glucan content in the immunostimulant may be, for example, 0.1 or more and 0.6 or less from the viewpoint of the interleukin production promoting effect.
- the ratio of the mannan content to the total glucan content in the immunostimulant may be preferably 0.14 or more, 0.18 or more, 0.2 or more, or 0.22 or more, and preferably 0.5 0.4 or less, 0.3 or less, 0.28 or less, or 0.26 or less.
- the ratio of the glycogen content to the total glucan content in the immunostimulant may be, for example, 0.11 or more and 0.3 or less from the viewpoint of the interleukin production promoting effect.
- the ratio of the glycogen content to the total glucan content in the immunostimulant may be preferably 0.11 or more, 0.12 or more, 0.13 or more, or 0.14 or more, and preferably 0.2. 0.18% or less, 0.16 or less, or 0.15 or less.
- Immunostimulants can exhibit high immunostimulatory activity despite the relatively low degree of purification of ⁇ -glucan. For example, by going through only a low-intensity extraction process under weak alkaline conditions, the active ingredient is effectively concentrated without excessive destruction of the three-dimensional structure of the yeast cell wall, and the form necessary and sufficient for immune response is obtained. This is probably because it has been retained. Alternatively, it can be considered that the immunostimulant contains a glucan composition produced by the method for producing a glucan composition described below.
- the immunostimulant may have a total carbohydrate content of, for example, 60% by mass or more and 70% by mass, preferably 62% by mass or more and 66% by mass or less.
- Carbohydrates include ⁇ -glucan, ⁇ -glucan, mannan, etc., as described above.
- the ⁇ -glucan content relative to the total carbohydrate content may be, for example, 35% by mass or more and 70% by mass or less, preferably 45% by mass or more, or 50% by mass or more, from the viewpoint of the effect of promoting interleukin production. and preferably 65% by mass or less, or 60% by mass or less.
- the immunostimulant may contain protein.
- the protein content in the immunostimulant may be, for example, 15% by mass or more and 25% by mass or less, preferably 18% by mass or more and 22% by mass or less.
- the ratio of the protein content to the ⁇ -glucan content in the immunostimulant may be, for example, 0.38 or more and 0.1 or less, preferably 0.45 or more, or It may be 0.5 or more, and preferably 0.8 or less, or 0.6 or less.
- the immunostimulant may contain lipids.
- the lipid content in the immunostimulant may be, for example, 10% by mass or more and 18% by mass or less, preferably 12% by mass or more and 16% by mass or less.
- the ratio of the lipid content to the ⁇ -glucan content in the immunostimulant may be, for example, 0.38 or more and 0.4 or less, preferably 0.39 or more, from the viewpoint of the effect of promoting interleukin production. and preferably 0.4 or less.
- the immunostimulant may contain ash.
- the content of ash in the immunostimulant may be, for example, 1.8% by mass or more and 3% by mass or less, preferably 1.9% by mass or more, and may be 2.2% by mass or less.
- the ratio of the ash content to the ⁇ -glucan content in the immunostimulant may be, for example, 0.04 or more and 0.065 or less, preferably 0.05 or more, from the viewpoint of the effect of promoting interleukin production. and preferably 0.06 or less.
- the immunostimulant may contain a water-insoluble component, and the water-insoluble component may contain an active ingredient.
- the immunostimulant may consist essentially of water-insoluble components.
- substantially means not excluding water-soluble components that are inevitably mixed, and means that the content of water-soluble components is, for example, less than 5% by mass, or less than 1% by mass. .
- the immunostimulant may contain a water-insoluble component and a water-soluble component.
- the content may be, for example, 1% by mass or more and less than 50% by mass, preferably 40% by mass or less or 20% by mass or less, and preferably 5% by mass. % or more.
- water-insoluble means that the solubility in 100 g of water at 25°C is less than 1 g, and water-soluble means that the solubility in 100 g of water at 25°C is 1 g or more. do.
- the immunostimulant may contain, for example, a third processed product obtained by the method for producing a glucan composition described later, or may consist of the third processed product.
- the immunostimulant may further contain known components having immunoregulatory action in addition to ⁇ -glucan, which is the main component.
- components having immunoregulatory action include beet tea extract, fucoidan, arabinoxylan, lactoferrin, catechin, chitosan, chitosan oligosaccharide, chitin oligosaccharide, L-ascorbic acid, coenzyme Q10 (including reduced form), and the like. can be done.
- Immunostimulants include, if necessary, any ingredient known to be commonly used in pharmaceuticals, foods, feeds, etc., such as water, fats and oils, sugars, vitamins, sweeteners, seasonings, Acidulants, preservatives, fragrances, coloring agents, excipients, bulking agents, binders, thickeners, stabilizers, emulsifiers, pH adjusters and the like can be blended.
- any ingredient known to be commonly used in pharmaceuticals, foods, feeds, etc. such as water, fats and oils, sugars, vitamins, sweeteners, seasonings, Acidulants, preservatives, fragrances, coloring agents, excipients, bulking agents, binders, thickeners, stabilizers, emulsifiers, pH adjusters and the like can be blended.
- the form of the immunostimulant may be solid such as powder or granules, liquid, paste, or the like.
- the dosage form of the immunopotentiating agent can be appropriately selected according to the administration method, administration subject, and the like.
- Dosage forms include, for example, formulations for oral administration such as tablets, capsules, granules, lozenges, powders, and liquids. These formulations can be produced according to known methods using additives such as excipients, lubricants, binders, disintegrants, stabilizers, flavoring agents and diluents.
- it is also possible to incorporate an immunostimulant into food compositions such as health foods and health supplements, beverage compositions, feeds, and the like.
- an immunostimulator When an immunostimulator is administered to a subject such as a vertebrate or invertebrate, it exhibits an immunostimulatory effect in the subject. This can suppress the onset of infectious diseases in the subject. That is, the immunostimulatory agent can be applied in a method of preventing infectious disease in a subject.
- Vertebrates to be administered include mammals, birds, fish and the like. Mammals may include humans and may be mammals other than humans. Mammals other than humans include pigs, cows, horses, sheep and monkeys, as well as pets such as dogs and cats. Examples of birds include meat chickens, laying hens, turkeys, ducks, and pigeons.
- Examples of fish include salmonids such as salmon, trout, trout, char, taimen, carp, crucian carp, tilapia, catfish, sea bass, yellowtail, amberjack, yellowtail, flounder, sea bream, tuna, and eel.
- Examples of invertebrates to be administered include arthropods such as crabs and shrimps, echinoderms such as sea urchins and sea cucumbers, mollusks such as octopus, squid and shellfish, and prochordates such as sea squirts.
- the immunostimulant When administered as a drug or food or drink, for example, it can be orally administered in an amount of 1 mg to 500 mg (dry weight)/kg body weight once to several times a day. Moreover, when it is used as food, drink, feed, or the like, 0.001 g to 1 g can be added per 100 g of food, drink, feed, or the like.
- an immunostimulant as a feed for example, for mammals, birds, and fish
- a mixture of 0.001% by mass or more and 1% by mass or less with respect to the feed to be administered is administered once to several times a day. can be administered once.
- a method for producing a glucan composition includes a washing step of washing yeast cell walls under alkaline conditions to obtain a first processed product, and a second processed product by heat-treating the first processed product under alkaline conditions. and a recovery step of recovering the third processed material as a solid content from the second processed material.
- the resulting third processed product has a ⁇ -glucan content of 25% by mass or more and 45% by mass or less, and has an excellent immunostimulatory effect.
- the third processed product has an excellent effect of promoting interleukin production, and is particularly excellent in promoting effect of interleukin-8 production.
- a glucan composition with excellent immunostimulatory effects can be efficiently produced. This can be attributed, for example, to the fact that the washing step efficiently concentrates the components that contribute to the immunostimulatory effect.
- the yeast cell wall used in the method for producing the glucan composition may be a commercially available product, or may be obtained, for example, by pretreating the raw material yeast.
- the pretreatment step of pretreating yeast as a raw material includes, for example, a self-digestion step of autolyzing yeast to obtain an autolysate, a hot water extraction step of extracting yeast with hot water to obtain a hot water extract, and a hot water extraction step of extracting yeast from yeast. Even if it includes a pre-decomposition step, which is alone or in combination such as an enzyme treatment step to obtain an enzyme-treated product by treatment, and a separation step to obtain yeast cell walls by centrifuging the pre-decomposed product that has undergone the pre-decomposition step. good.
- yeasts of the genus Saccharomyces include yeasts of the genus Saccharomyces, Schizosaccharomyces, Kluyveromyces, Candida, Pichia, Torulopsis, etc. At least one selected from the group consisting of these can be used. It preferably contains, and more preferably contains at least Saccharomyces yeast.
- Yeast belonging to the genus Saccharomyces includes food yeast such as brewer's yeast and baker's yeast.
- food yeast include brewing yeast such as beer yeast, low-malt beer yeast, miscellaneous sake yeast, sake yeast, wine yeast, and whiskey yeast, baker's yeast, and torula yeast.
- yeast proteins are decomposed by the protease of the yeast itself to obtain autolysates.
- the self-digestion step is carried out, for example, by adjusting the pH to 2 to 7 and the temperature to 40° C. or higher and 65° C. or lower for 1 hour or longer and 48 hours or shorter.
- the autolysate is centrifuged to obtain a fraction containing yeast cell walls as a heavy liquid.
- a nozzle type centrifuge, an intermittent discharge type centrifuge, a sharpless type centrifuge, etc. can be used. can be adjusted accordingly.
- the washing step the yeast cell walls are washed under alkaline conditions to obtain the first processed product.
- Any washing method may be used as long as it can remove at least part of proteins, amino acids, etc. remaining in the yeast cell wall.
- the washing method may include, for example, mixing the yeast cell walls and a liquid medium to form a washing liquid comprising the yeast cell walls, and removing at least a portion of the liquid medium from the washing liquid.
- the liquid medium may contain at least water and an alkaline substance.
- the method for removing the liquid medium from the washing liquid may be appropriately selected from commonly used solid-liquid separation methods.
- the solid-liquid separation method includes, for example, a centrifugal method using a yeast separator or the like, a method using a filter, an ultrafiltration membrane, or the like.
- Washing of the yeast cell walls is carried out by adjusting the washing liquid containing the yeast cell walls to pH 8 or more and pH 14 or less, preferably pH 9.5 or more and pH 12 or less, and performing solid-liquid separation with a centrifuge (e.g., yeast separator) while adding water.
- the cleaning liquid may contain at least water as a liquid medium.
- a wash solution containing yeast cell walls can be adjusted to a desired pH by adding an alkaline substance to the wash solution.
- alkaline substances include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, alkaline earth metal hydroxides such as calcium hydroxide, and alkali metal carbonates such as sodium carbonate.
- An alkaline substance may be used as an aqueous solution to adjust the pH.
- Solid-liquid separation in washing the yeast cell walls may include centrifugation while adding water.
- water For adding water, only water may be used, or an alkaline aqueous solution containing an alkaline substance may be used.
- the alkaline aqueous solution may have, for example, pH 8 or more and pH 14 or less, preferably pH 9.5 or more and pH 12 or less.
- the washing temperature in the washing step may be, for example, 4°C or higher and 95°C or lower, preferably 20°C or higher and 50°C or lower. Washing may also be carried out, for example, until the liquid, which is solid-liquid separated by centrifugation, turns from colorless to pale or transparent.
- the first processed material obtained in the washing step may be water-insoluble, or may be a water-insoluble solid. Moreover, the first processed material may be in the form of a slurry containing yeast cell walls, which are water-insoluble solids.
- the first treated material is heat treated under alkaline conditions to obtain the second treated material.
- the heat treatment under alkaline conditions may be an alkaline hydrolysis treatment of the first processed material.
- the heat treatment step may include obtaining a mixture containing the first processed product, the alkaline substance, and the liquid medium, heating the mixture to a predetermined temperature, and maintaining the mixture at the predetermined temperature for a predetermined time.
- the mixture may be stirred or left standing. Further, when the mixture is maintained at a predetermined temperature, a temperature variation of, for example, ⁇ 10°C, preferably ⁇ 5°C is allowed.
- the alkaline conditions for heat-treating the first processed material may be, for example, pH 8 or more and 14 or less, preferably pH 9 or more, and preferably pH 12 or less.
- the alkaline conditions for heat-treating under alkaline conditions with a relatively low pH there is a tendency to obtain a glucan composition with a more excellent immunostimulatory effect.
- the pH of the first processed product can be adjusted to a desired pH by adding the alkaline substance described above to the slurry.
- the addition method may be a batch system or a continuous system.
- the amount of the alkaline substance added for adjusting the above pH may be, for example, 0.01% by mass or more and 1% by mass or less, preferably 0.05% by mass or more, relative to the mixture, Moreover, it may preferably be 0.5% by mass or less.
- the temperature of the heat treatment may be, for example, 60°C or higher and 120°C or lower, preferably 70°C or higher or 75°C or higher, and preferably 110°C or lower or 95°C or lower.
- the heat treatment time may be, for example, 3 hours or more and 24 hours or less, preferably 12 hours or more, and preferably 20 hours or less.
- the heat treatment atmosphere may be, for example, an air atmosphere.
- the second processed material obtained in the heat treatment step may be, for example, in the form of a slurry containing water-insoluble solids, and may have a solid content of 10% by mass or more and 20% by mass or less.
- the third processed material containing the solid content is recovered from the second processed material obtained in the heat treatment step.
- the second processed material to be subjected to the recovery step may be neutralized or in an alkaline state.
- the recovery of the solid content from the second processed material can be carried out by solid-liquid separation of the second processed material.
- solid-liquid separation for example, a centrifugal separation method, a method using a filter, an ultrafiltration membrane, or the like can be used.
- the third processed material may be recovered as a wet cake containing water, or may be recovered as a slurry containing solids.
- the content of solids in the third processed material may be, for example, 5% by mass or more, preferably 10% by mass or more, or higher than 20% by mass.
- the method for producing a glucan composition may further include a drying step of drying the third processed product.
- a spray dryer, a freeze dryer, a drum dryer, or the like can be used for the drying step.
- a sterilization step of sterilizing the third processed material may be provided before the drying step.
- the sterilization step can be carried out by heat treatment at 120° C. or higher for 10 to 60 seconds using a UHT sterilizer, for example, but can be adjusted as appropriate so as to meet the desired quality.
- a glucan composition obtained by a method for producing a glucan composition may be an immunostimulator because it has an excellent immunostimulatory effect.
- the glucan composition since it has an excellent effect of promoting interleukin production, it may be an interleukin production promoter, preferably an interleukin-8 production promoter.
- the method for producing a glucan composition may include obtaining a yeast-derived water-soluble polysaccharide in addition to obtaining the glucan composition.
- the yeast-derived water-soluble polysaccharide can be recovered from the supernatant solution separated from the second processed product. Specifically, yeast-derived of water-soluble polysaccharides can be obtained.
- the resulting yeast-derived water-soluble polysaccharide has excellent water solubility, low viscosity in an aqueous solution, and a high mannan content. That is, the method for producing a glucan composition may include a method for producing a mannan composition.
- the content of mannan in the yeast-derived water-soluble polysaccharide may be, for example, 40% by mass or more and 80% by mass or less.
- the heat treatment of the supernatant solution under acidic conditions may be performed, for example, under acidic conditions of pH 2.5 or higher and pH 5 or lower, preferably pH 3.5 or higher and pH 4.5 or lower.
- the heat treatment temperature may be, for example, 90° C. or higher and 120° C. or lower, preferably 95° C. or higher and 115° C. or lower.
- the heat treatment time may be, for example, 15 seconds or more and 120 seconds or less, preferably 30 seconds or more and 90 seconds or less.
- centrifugation diatomaceous earth filtration, and ultrafiltration membranes can be used to remove the coagulum generated by heat treatment.
- a spray dryer, a freeze dryer, a drum dryer, or the like can be used for the drying treatment of the solution from which the coagulum has been removed.
- Immunostimulatory methods may comprise administering to a subject an immunostimulatory agent comprising the glucan composition described above.
- the subject may be a vertebrate, invertebrate, or the like. Details of subjects and doses are as described above.
- Another aspect of the present invention includes the use of a glucan composition in the production of an immunostimulator used in an immunostimulatory method, the use of a glucan composition in an immunostimulatory method, and the glucan composition used in an immunostimulatory method. .
- Example 1 Prepare a yeast cell wall (15% solid content, derived from yeast autolysate) derived from brewer's yeast belonging to the genus Saccharomyces manufactured at Tochigi Koganei Factory of Asahi Group Foods Co., Ltd. Yeast glucan according to the following method. A composition was obtained.
- yeast cell walls were washed under alkaline conditions while water and sodium hydroxide were added to obtain a first processed product with a pH adjusted to 10 or more and 11 or less.
- the mixture was heat-treated at a temperature of 80° C. or higher and 90° C. or lower for 17 hours to obtain a second processed product.
- the obtained second processed product was centrifuged to obtain a third processed product as a heavy liquid.
- the resulting third processed product was dried using a drum dryer to obtain the glucan composition of Example 1 (YG35).
- Comparative example 1 The yeast cell wall prepared in Example 1 was dried to obtain the glucan composition (YCW) of Comparative Example 1.
- Comparative example 2 The glucan composition (YG35) of Example 1 was purified with protease and then freeze-dried to obtain the glucan composition (YG45) of Comparative Example 2.
- Comparative example 3 The glucan composition of Comparative Example 2 (YG45) was purified by removing lipids using an organic solvent, and then freeze-dried to obtain the glucan composition of Comparative Example 3 (YG55).
- Table 1 shows the results.
- the contents of ⁇ -glucan, ⁇ -glucan and mannan are the contents of the entire glucan composition as part of carbohydrates, and the content of glycogen is the glucan composition as part of ⁇ -glucan. It is the content rate for the whole product.
- ⁇ -Glucan Sample Each of the glucan compositions obtained above was sonicated for 3 minutes while cooling on ice to obtain a dispersion. Pig-derived pepsin was added to each of the obtained dispersions, and pepsin treatment was performed at 39° C. for 2 hours. Next, porcine-derived pancreatin was added and pancreatin treatment was performed at 39° C. for 4 hours to prepare each ⁇ -glucan sample.
- the isolated neutrophils were suspended in RPMI1640 medium and seeded in a 24-well multiwell plate at 2 ⁇ 10 5 cells/well. Similarly, peripheral blood mononuclear cells (PBMC) were seeded at 2 ⁇ 10 7 cells/well. Thereafter, the cells were cultured under conditions of 5% CO 2 and 37° C. for 2 hours, neutrophils or monocytes in the PBMC were adhered, and the supernatant was removed. Each ⁇ -glucan sample was added to a concentration of 20 ⁇ g/ml and cultured for 24 hours, after which the supernatant was collected and IL-8 production was measured using a commercially available ELISA kit.
- PBMC peripheral blood mononuclear cells
- FIG. 1 shows the results of using the glucan compositions of Example 1 and Comparative Example 1. Significant difference (p ⁇ 0.01) was observed by t-test.
- FIG. 2 shows the results of using the glucan compositions of Example 1 and Comparative Examples 2 and 3. A one-way ANOVA was performed, and a significant difference was observed overall (p ⁇ 0.05). Therefore, when all group multiple comparisons were performed by the Bonferroni method, Example 1 had a significant difference (p ⁇ 0.01) with respect to Comparative Example 2, and a significant difference (p ⁇ 0.05) with respect to Comparative Example 3. was accepted.
- the glucan composition (YG35) containing about 35% by mass of ⁇ -glucan exhibits a high immunostimulatory effect. Also, it can be seen that the glucan composition (YG35) exhibits a significantly higher immunostimulatory effect than the more purified glucan composition (YG45) and the glucan composition (YG55).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Materials Engineering (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Sustainable Development (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
免疫賦活剤は、酵母細胞壁に由来するβ-グルカンを含み、免疫賦活剤中のβ-グルカンの含有率が、例えば、25質量%以上45質量%以下であるグルカン組成物である。本実施形態に係る免疫賦活剤は、所定の含有率で酵母細胞壁由来のβ-グルカンを含むことで優れた免疫賦活効果を有する。これにより、家畜、ヒト、養殖魚等における感染症の罹患、進行を抑制することが期待されるだけでなく、薬剤耐性菌発生の脅威を軽減する手段を提供しうる。
グルカン組成物の製造方法は、酵母細胞壁をアルカリ性条件下で洗浄して第1処理物を得る洗浄工程と、第1処理物をアルカリ条件下で熱処理して第2処理物を得る熱処理工程と、第2処理物から固形分として第3処理物を回収する回収工程と、を含む。得られる第3処理物は、β-グルカンの含有率が25質量%以上45質量%以下であり、優れた免疫賦活効果を有する。また第3処理物は、優れたインターロイキン産生促進効果を有し、特にインターロイキン8産生促進効果に優れる。
洗浄工程では、酵母細胞壁をアルカリ条件下で洗浄して第1処理物を得る。洗浄方法は、酵母細胞壁に残留するタンパク質、アミノ酸等の少なくとも一部を除去できる方法であればよい。洗浄方法は、例えば酵母細胞壁と液媒体とを混合して酵母細胞壁を含む洗浄液を調製し、洗浄液から液媒体の少なくとも一部を除去することを含んでいてよい。液媒体は少なくとも水とアルカリ性物質を含んでいてよい。洗浄液からの液媒体の除去方法は、通常用いられる固液分離方法から適宜選択すればよい。固液分離方法としては、例えばイーストセパレーター等による遠心分離法、濾過器、限外濾過膜等を用いる方法等が挙げられる。
熱処理工程では、第1処理物をアルカリ条件下で熱処理して第2処理物を得る。アルカリ条件での熱処理は、第1処理物のアルカリ加水分解処理であってよい。熱処理工程は、第1処理物とアルカリ性物質と液媒体とを含む混合物を得ることと、混合物を所定温度まで昇温することと、混合物を所定温度で所定時間維持することとを含んでいてよい。熱処理工程では、混合物を撹拌してもよいし、静置したままであってもよい。また、混合物を所定温度に維持する際には、例えば±10℃、好ましくは±5℃程度の温度変動が許容される。
回収工程では、熱処理工程で得られた第2処理物から固形分を含む第3処理物を回収する。回収工程に供される第2処理物は、中和されていてもよいし、アルカリ性の状態であってもよい。第2処理物からの固形分の回収は、第2処理物を固液分離することで実施することができる。固液分離には、例えば、遠心分離法、濾過器、限外濾過膜等を用いる方法等を用いることができる。遠心分離にはイーストセパレーター、ノズル型遠心機、間欠排出型遠心機、シャープレス遠心機等を用いることができる。
免疫賦活方法は、上述したグルカン組成物を含む免疫賦活剤を対象に投与することを含んでいてよい。対象は脊椎動物、無脊椎動物等であってよい。対象の詳細、投与量については既述の通りである。
アサヒグループ食品(株)栃木小金井工場にて製造したサッカロマイセス(Saccharomyces)属に属するビール酵母に由来する酵母細胞壁(固形分15%、酵母の自己消化物由来)を準備し、以下の方法に従って酵母グルカン組成物を取得した。
実施例1で準備した酵母細胞壁を乾燥処理して、比較例1のグルカン組成物(YCW)とした。
実施例1のグルカン組成物(YG35)を、プロテアーゼによって精製処理したのち、凍結乾燥処理して比較例2のグルカン組成物(YG45)とした。
比較例2のグルカン組成物(YG45)を、有機溶媒を用いて脂質を除去する精製処理を行ったのち、凍結乾燥処理して比較例3のグルカン組成物(YG55)とした。
上記で得られたグルカン組成物をそれぞれ、氷冷しながら3分間超音波処理して分散物を得た。得られた分散物にそれぞれ、ブタ由来ペプシンを添加して39℃、2時間のペプシン処理を行った。次いでブタ由来パンクレアチンを添加して39℃、4時間のパンクレアチン処理を行って、β-グルカンサンプルをそれぞれ調製した。
10週齢の離乳子豚6頭の頸静脈から、ヘパリン管に末梢血を採血した。その後68%と75%のパーコール溶液を用いた不連続密度勾配遠心法により、リンパ球・単球・血小板などから好中球を分離した。74.7%塩化アンモニウムで赤血球を溶血し、350×g・18℃・10分間の遠心分離後、沈殿をRPMI1640培地で3回洗浄し、106cells/mlとなるように懸濁した。
単離した好中球をRPMI1640培地に懸濁し、2×105cells/wellとなるように24穴マルチウェルプレートに播種した。同様に末梢血単核球(PBMC)は2×107cells/wellとなるように播種した。その後、5%CO2・37℃の条件下で2時間培養し、好中球もしくはPBMC中の単球を付着させ上清を除去した。各β-グルカンサンプルを20μg/mlの濃度になるよう添加して24時間培養した後、上清を回収し市販のELISAキットを用いて、IL-8産生量を測定した。
Claims (15)
- 酵母細胞壁に由来するβ-グルカンを含み、β-グルカンの含有率が25質量%以上45質量%以下である免疫賦活剤。
- マンナンを更に含み、前記免疫賦活剤における前記マンナンの含有率が5質量%以上20質量%以下である請求項1に記載の免疫賦活剤。
- 前記β-グルカンに対する前記マンナンの含有比が0.1以上1未満である請求項2に記載の免疫賦活剤。
- α-グルカンを更に含み、前記免疫賦活剤における前記α-グルカンの含有率が7質量%以上12質量%以下である請求項1から3のいずれか1項に記載の免疫賦活剤。
- 前記β-グルカンに対する前記α-グルカンの含有比が0.15以上0.55以下である請求項4に記載の免疫賦活剤。
- 前記α-グルカンはグリコーゲンを含み、前記免疫賦活剤における前記グリコーゲンの含有率が4質量%以上10質量%以下である請求項4又は5に記載の免疫賦活剤。
- 前記β-グルカンに対する前記グリコーゲンの含有比が0.16以上0.5以下である請求項6に記載の免疫賦活剤。
- 酵母細胞壁に由来するβ-グルカンを含み、β-グルカンの含有率が25質量%以上45質量%以下であるインターロイキン8産生促進剤。
- 酵母細胞壁をアルカリ性条件下で洗浄して第1処理物を得ることと、前記第1処理物をアルカリ条件下で熱処理して第2処理物を得ることと、前記第2処理物から固形分として第3処理物を回収することと、を含み、
前記第3処理物は、β-グルカンの含有率が25質量%以上45質量%以下である、グルカン組成物の製造方法。 - 前記アルカリ条件下での熱処理は、pH8以上pH14以下、70℃以上110℃以下の条件で行われる請求項9に記載の製造方法。
- 前記酵母細胞壁は、醸造用酵母又はパン酵母に由来する細胞壁を含む請求項9又は10に記載の製造方法。
- 前記アルカリ条件下での洗浄は、前記酵母細胞壁を含む洗浄液をpH8以上pH14以下に調整することと、加水しながら遠心分離機で固液分離することとを含む請求項9から11のいずれか1項に記載の製造方法。
- 前記第3処理物は、前記第2処理物を遠心分離により固液分離して回収される請求項9から12のいずれか1項に記載の製造方法。
- 前記グルカン組成物は、免疫賦活剤である請求項9から13のいずれか1項に記載の製造方法。
- 前記グルカン組成物は、インターロイキン8産生促進剤である請求項9から14のいずれか1項に記載の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22804494.7A EP4342477A1 (en) | 2021-05-21 | 2022-04-20 | Immunostimulator and glucan composition production method |
KR1020237039323A KR20240011139A (ko) | 2021-05-21 | 2022-04-20 | 면역 부활제 및 글루칸 조성물의 제조 방법 |
AU2022278209A AU2022278209A1 (en) | 2021-05-21 | 2022-04-20 | Immunostimulator and glucan composition production method |
BR112023023636A BR112023023636A2 (pt) | 2021-05-21 | 2022-04-20 | Imunoestimulante, promotor da produção de interleucinas 8, e, método de produção de uma composição de glucanos |
CN202280034801.2A CN117295502A (zh) | 2021-05-21 | 2022-04-20 | 免疫刺激剂和葡聚糖组合物的制备方法 |
JP2023522573A JPWO2022244580A1 (ja) | 2021-05-21 | 2022-04-20 | |
US18/289,021 US20240226135A1 (en) | 2021-05-21 | 2022-04-20 | Immunostimulator and method of producing glucan composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021086394 | 2021-05-21 | ||
JP2021-086394 | 2021-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022244580A1 true WO2022244580A1 (ja) | 2022-11-24 |
Family
ID=84141256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/018278 WO2022244580A1 (ja) | 2021-05-21 | 2022-04-20 | 免疫賦活剤及びグルカン組成物の製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240226135A1 (ja) |
EP (1) | EP4342477A1 (ja) |
JP (1) | JPWO2022244580A1 (ja) |
KR (1) | KR20240011139A (ja) |
CN (1) | CN117295502A (ja) |
AU (1) | AU2022278209A1 (ja) |
BR (1) | BR112023023636A2 (ja) |
TW (1) | TW202313070A (ja) |
WO (1) | WO2022244580A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253703A (ja) * | 1990-07-06 | 1992-09-09 | Phillips Petroleum Co | 酵母グルカンの製造方法 |
JPH11501691A (ja) * | 1995-03-13 | 1999-02-09 | ノボゲン リサーチ ピーティーワイ.リミテッド. | グルカンの製造方法、及びグルカンの治療用途 |
JP2004210895A (ja) * | 2002-12-27 | 2004-07-29 | Immudyne Japan:Kk | 免疫機能を有する可能性β−グルカンの製造方法及び用途 |
JP2007254425A (ja) * | 2006-03-24 | 2007-10-04 | Adeka Corp | βグルカン組成物、健康補助食品及び健康食品 |
JP2010533479A (ja) | 2008-04-29 | 2010-10-28 | 安▲チ▼酵母股▲フェン▼有限公司 | グルカンとマンナンを調製する方法、それによって得られたグルカン調製物とマンナン調製物、およびその用途 |
JP2018050488A (ja) * | 2016-09-26 | 2018-04-05 | 株式会社キティー | 免疫賦活用組成物 |
WO2020003905A1 (ja) * | 2018-06-27 | 2020-01-02 | アサヒグループホールディングス株式会社 | インターロイキン-6、10産生促進剤 |
WO2020075424A1 (ja) * | 2018-10-09 | 2020-04-16 | アサヒグループホールディングス株式会社 | 免疫賦活剤及び感染予防方法 |
JP2021086394A (ja) | 2019-11-28 | 2021-06-03 | 横河電機株式会社 | システム、方法、および、プログラム |
-
2022
- 2022-04-20 EP EP22804494.7A patent/EP4342477A1/en active Pending
- 2022-04-20 CN CN202280034801.2A patent/CN117295502A/zh active Pending
- 2022-04-20 AU AU2022278209A patent/AU2022278209A1/en active Pending
- 2022-04-20 JP JP2023522573A patent/JPWO2022244580A1/ja active Pending
- 2022-04-20 BR BR112023023636A patent/BR112023023636A2/pt unknown
- 2022-04-20 WO PCT/JP2022/018278 patent/WO2022244580A1/ja active Application Filing
- 2022-04-20 US US18/289,021 patent/US20240226135A1/en active Pending
- 2022-04-20 KR KR1020237039323A patent/KR20240011139A/ko unknown
- 2022-04-27 TW TW111115977A patent/TW202313070A/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253703A (ja) * | 1990-07-06 | 1992-09-09 | Phillips Petroleum Co | 酵母グルカンの製造方法 |
JPH11501691A (ja) * | 1995-03-13 | 1999-02-09 | ノボゲン リサーチ ピーティーワイ.リミテッド. | グルカンの製造方法、及びグルカンの治療用途 |
JP2004210895A (ja) * | 2002-12-27 | 2004-07-29 | Immudyne Japan:Kk | 免疫機能を有する可能性β−グルカンの製造方法及び用途 |
JP2007254425A (ja) * | 2006-03-24 | 2007-10-04 | Adeka Corp | βグルカン組成物、健康補助食品及び健康食品 |
JP2010533479A (ja) | 2008-04-29 | 2010-10-28 | 安▲チ▼酵母股▲フェン▼有限公司 | グルカンとマンナンを調製する方法、それによって得られたグルカン調製物とマンナン調製物、およびその用途 |
JP2018050488A (ja) * | 2016-09-26 | 2018-04-05 | 株式会社キティー | 免疫賦活用組成物 |
WO2020003905A1 (ja) * | 2018-06-27 | 2020-01-02 | アサヒグループホールディングス株式会社 | インターロイキン-6、10産生促進剤 |
WO2020075424A1 (ja) * | 2018-10-09 | 2020-04-16 | アサヒグループホールディングス株式会社 | 免疫賦活剤及び感染予防方法 |
JP2021086394A (ja) | 2019-11-28 | 2021-06-03 | 横河電機株式会社 | システム、方法、および、プログラム |
Non-Patent Citations (4)
Title |
---|
JUNG-NAM LEE, BIOSCI. BIOTECHNOL. BIOCHEM., vol. 65, no. 4, 2001, pages 837 - 841 |
JUNG-NAM LEE, DO-YOUN LEE, IN-HYE JI, GI-EUN KIM, HYE NAM KIM, JEONGWON SOHN, SANGDUK KIM, CHAN-WHA KIM: " Purification of Soluble β-Glucan with Immune-enhancing Activity from the Cell Wall of Yeast. Biosci. ", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, JP, vol. 65, no. 4, 1 January 2001 (2001-01-01), JP , pages 837 - 841, XP093006932, ISSN: 0916-8451, DOI: 10.1271/bbb.65.837 * |
M. MEDINA-GALI REGLA, ORTEGA-VILLAIZAN MARÍA DEL MAR, MERCADO LUIS, NOVOA BEATRIZ, COLL JULIO, PEREZ LUIS: "Beta-glucan enhances the response to SVCV infection in zebrafish", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS., US, vol. 84, 1 July 2018 (2018-07-01), US , pages 307 - 314, XP093006933, ISSN: 0145-305X, DOI: 10.1016/j.dci.2018.02.019 * |
TOSHIRO YADOMAE: "Structure and biological activity of fungal β-1,3-glucans", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 5, 1 January 2000 (2000-01-01), pages 413 - 431, XP093006926, ISSN: 0031-6903 * |
Also Published As
Publication number | Publication date |
---|---|
AU2022278209A1 (en) | 2023-11-09 |
BR112023023636A2 (pt) | 2024-01-30 |
JPWO2022244580A1 (ja) | 2022-11-24 |
CN117295502A (zh) | 2023-12-26 |
EP4342477A1 (en) | 2024-03-27 |
TW202313070A (zh) | 2023-04-01 |
US20240226135A1 (en) | 2024-07-11 |
KR20240011139A (ko) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI652992B (zh) | 酵母來源之調味料、酵母蛋白質組成物之製造方法、及酵母來源之調味料之製造方法 | |
WO2015099153A1 (ja) | 養魚用飼料 | |
JP2009051836A (ja) | 治療剤 | |
CN1415757A (zh) | 一种用酶水解法从蝇蛆中提取蛋白质和甲壳素及用甲壳素制备壳聚糖的方法 | |
WO2020075424A1 (ja) | 免疫賦活剤及び感染予防方法 | |
JP2008118887A (ja) | 飲食品及び苦味マスキング剤 | |
JP2010285421A (ja) | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 | |
WO2022244580A1 (ja) | 免疫賦活剤及びグルカン組成物の製造方法 | |
JPH08266255A (ja) | 学習能力向上組成物 | |
JPH06256208A (ja) | 免疫賦活剤 | |
JP2013039087A (ja) | プロテオグリカンを含有してなる飲料水及びその製造方法 | |
JP7254798B2 (ja) | インターロイキン-6、10産生促進剤 | |
JP2003245055A (ja) | 肌改善用食品組成物及び肌改善方法 | |
EP3713427A1 (en) | Endoglucanase-treated glucans | |
JPH11228602A (ja) | 免疫力強化剤及び免疫力強化食品 | |
JP2002275087A (ja) | 抗糖尿病剤および糖尿病予防食品 | |
JP2002027922A (ja) | 免疫賦活剤および飼料 | |
JPH06234651A (ja) | 魚類の感染症の予防用薬剤 | |
JP4032726B2 (ja) | 魚介類の飼育方法及び飼料 | |
JPH07108859B2 (ja) | 魚類の感染症予防用薬剤 | |
JP2001322942A (ja) | 免疫賦活剤 | |
JPH08283175A (ja) | 免疫増強剤並びにそれを含有する甲殻類、魚類及び家畜用飼料 | |
JP2011241192A (ja) | 甲殻類の疾病防除剤およびこれを含有する飼料 | |
JP2004173620A (ja) | α−マンノビオース含有飼料 | |
JP2006241020A (ja) | 免疫系賦活剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22804494 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023522573 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022278209 Country of ref document: AU Ref document number: 2022278209 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18289021 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022278209 Country of ref document: AU Date of ref document: 20220420 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280034801.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301007574 Country of ref document: TH |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023023636 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022804494 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022804494 Country of ref document: EP Effective date: 20231221 |
|
ENP | Entry into the national phase |
Ref document number: 112023023636 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231110 |